## OMC: Omnicom Group Inc. - XLC: Communication Services

### Executive Summary

No thesis match: MRS_20 3.1% below STRENGTH zone (4.0-10.0%); PEG 16.57 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-9.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Osaic Holdings Inc. Has $8.12 Million Stock Position in Omnicom Group Inc. $OMC**
- Source: MarketBeat | 20251222T103542 | Somewhat-Bullish | Relevance: 100%
- Osaic Holdings Inc. significantly increased its stake in Omnicom Group Inc. by 289.6% to 102,184 shares, valued at $8.12 million, during Q2. Omnicom also raised its quarterly dividend to $0.80 per share, resulting in a 4.0% yield. Analysts have a "Hold" consensus rating with an average target price of $92.57 for Omnicom.

**2. Omnicom Group offers strategic insights for CES 2024**
- Source: Traders Union | 20251223T230924 | Somewhat-Bullish | Relevance: 100%
- Omnicom Group is providing strategic insights for businesses and agencies attending CES 2024, aiming to help them navigate the vast innovations and opportunities presented at the event. They have developed CES Preview Reports to highlight key strategic trends and innovations, enabling companies to focus their efforts efficiently. This initiative helps businesses discern what truly matters for their operations amidst the expansive technology showcase.

**3. Omnicom Group Inc. (NYSE:OMC) Receives Consensus Recommendation of "Hold" from Analysts**
- Source: MarketBeat | 20251223T065012 | Somewhat-Bullish | Relevance: 100%
- MarketBeat reports that Omnicom Group Inc. (NYSE:OMC) has received a consensus "Hold" recommendation from nine analysts, with an average 12-month price target of $92.57. The company recently increased its quarterly dividend to $0.80 per share, yielding 4.0%, and reported strong Q3 earnings of $2.24 EPS on $4.04 billion in revenue. Institutional investors hold a significant portion of the stock.

**4. WPP and Publicis Win Big In Kenvue Global Review**
- Source: ADWEEK | 20251222T180749 | Somewhat-Bullish | Relevance: 74%
- Kenvue has selected WPP and Publicis Groupe as its new global agency partners following a competitive review. WPP will handle creative and production for most Kenvue brands, while Publicis will manage media, commerce, healthcare, and technology support, including creative for Neutrogena. This decision follows a year of challenges and leadership changes for Kenvue, particularly concerning its Tylenol brand.

**5. Publicis Media Wins Kenvue's $1.3B Global Business 12/23/2025**
- Source: MediaPost | 20251223T160749 | Somewhat-Bullish | Relevance: 61%
- Publicis Media has won Kenvue's global media business, which is estimated at $1.35 billion annually. Publicis will handle media, commerce, healthcare professional, and technology support, as well as creative and production for the Neutrogena brand. WPP will lead creative and production for all other Kenvue brands.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | UBS | $108 | $99 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.4%)
- Blackrock Inc.: 10.7% (+0.7%)
- State Street Corpora: 8.7% (+15.8%)
- JPMORGAN CHASE & CO: 8.4% (+160.9%)
- Massachusetts Financ: 3.9% (-5.5%)

### Key Risks

1. Valuation stretched: PEG 16.6x requires aggressive growth execution.
2. Elevated short interest (10.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 16.57 signals overvaluation risk, limited margin of safety. Forward P/E 8.1x attractive for 15% earnings growth. Quality metrics strong (ROE 27%). Revenue growth strong at 23% YoY. Analyst sentiment positive (1 raises, avg +9%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.0B |
| Beta | 0.76 |
| 52W Range | $68.37 - $89.35 |
| Short Interest | 10.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 16.57 |
| Forward P/E | 8.1 |
| Current P/E | 9.3 |
| YoY Growth | 15.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 12.7% to 3.1% (-9.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.9pp (needs >4.0% for momentum thesis). MRS_5 (-3.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.2% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.11% (CS: 82) | Neutral |
| RSI_14 | 55.9 | Neutral |
| MACD Histogram | 0.42 | Bullish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.041x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.68
- **Stop Loss:** $74.50 (5.3% risk)
- **Target:** $82.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 287
- **Position Value:** $22,581.16
- **Portfolio %:** 22.58%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-10 (Est: $2.63)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.24 | +3.1% |
| 2025Q2 | $2.03 | $2.05 | +0.8% |
| 2025Q1 | $1.66 | $1.70 | +2.3% |
| 2024Q4 | $2.39 | $2.41 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*